List of Excipients in API atrasentan
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing atrasentan
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | CROSPOVIDONE | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | CYSTEINE HYDROCHLORIDE | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | GLYCERYL DIBEHENATE | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | HYPROMELLOSE | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | LACTOSE MONOHYDRATE | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | POLYETHYLENE GLYCOL | 2030-04-02 |
| Novartis Pharmaceuticals Corporation | VANRAFIA | atrasentan | 0078-1420 | SILICON DIOXIDE | 2030-04-02 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for atrasentan
Excipient focus: CROSPOVIDONE
atrasentan drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CYSTEINE HYDROCHLORIDE
atrasentan drug variants containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL DIBEHENATE
atrasentan drug variants containing GLYCERYL DIBEHENATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing GLYCERYL DIBEHENATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
atrasentan drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
atrasentan drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
atrasentan drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
atrasentan drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | atrasentan | 0078-1420 |
| >Company | >Ingredient | >NDC |
atrasentan drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch